Market news

Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple. The group’s ability to turn its plasma based operations into...

Toronto, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The union that represents Canadian Blood Services (CBS) workers in Ontario is calling for an immediate termination of the blood-plasma collection contract with for-profit Spanish pharmaceutical company Grifols. OPSEU/SEFPO is also calling for an ironclad commitment to ensure that blood and plasma services are never again operated on a for-profit basis. Two people died after donating plasma at Grifols-operated facilities in Winnipeg in October 2025 and J

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXOD/FOXO) ( “FOXO”) subsidiary, Vector BioSource, Inc. (“Vector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the “Agreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector’s customers to augment its existing sourcing

Motley Fool Press Release.

Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy. Chief Executive Officer Nacho

Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

Grifols (BME:GRF) has started dosing patients in two Phase 3 trials for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY, aiming to expand their U.S. labels and potentially broaden future treatment options. See our latest analysis for Grifols. These new Phase 3 trials come as Grifols shares trade at €9.85, with a 90 day share price return of 10.36% but a year to date share price return that has declined 12.05%, and a 1 year total shareholder return that has fallen 19.51%. This suggests...

Detailed price information for Grifols S.A. ADR (GRFS-Q) from The Globe and Mail including charting and trades.

TORONTO, July 13, 2026 (GLOBE NEWSWIRE) -- Will Trial Lawyers and the Ontario Health Coalition invite members of the media to attend a press conference regarding patient safety issues related to Grifols, one of the world's largest manufacturers of plasma-derived medical products. The media conference will examine issues surrounding public safety and reported adverse events; patients’ legal rights and available supports; regulatory oversight, transparency, and accountability. Speakers will discus